The effect of comorbidity on survival and collected CD34+cell counts in autologous hematopoietic stem cell transplant patients
TRANSFUSION AND APHERESIS SCIENCE, cilt.61, sa.1, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 61 Sayı: 1
- Basım Tarihi: 2022
- Doi Numarası: 10.1016/j.transci.2021.103296
- Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, EMBASE, MEDLINE
- Anahtar Kelimeler: Autologous stem cell transplantation, Lymphoma, Multiple myeloma, Hematopoietic cell transplantation-specific co, morbidity index, Engraftment time, INDEX HCT-CI, REDUCED-INTENSITY, LYMPHOMA PATIENTS, MULTIPLE-MYELOMA, ELDERLY-PATIENTS, PREDICTS, OUTCOMES, BLOOD, MORTALITY
- İnönü Üniversitesi Adresli: Evet
Özet
Objective: In this study, we aimed to report the effectiveness of hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and GATMO scores in predicting overall survival (OS) who underwent autologous stem cell transplantation (ASCT). Material and methods: The data of 263 MM and 204 lymphoma patients who underwent ASCT in the last 11 years were retrospectively analyzed. Results: Neutrophil engraftment time, thrombocyte engraftment time and collected CD34+ cell counts were similar in MM patients with HCT-CI 2 (all p 2 tended to be higher than those with HCT-CI 2 was 51.5 months, the estimated median OS of patients with HCT-CI 2 was 9.5 months (p=0.012). When lymphoma patients were divided into four groups according to their GATMO scores, the OS of the four groups was found to be different from each other (p<0.001). Conclusion: HCT-CI and GATMO scores predict OS in lymphoma patients but not MM patients.